GoodRx Holdings, Inc. (GDRX) Misses Q4 EPS by 1c; Guides Q1 Revs Below the Street
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to GoodRx Holdings, Inc. (GDRX) Misses Q4 EPS by 1c; Guides Q1 Revs Below the Street
March 1, 2022 6:58 AM EST
Goldman Sachs analyst Eric Sheridan lowered the price target on GoodRx Holdings Inc. (NASDAQ: GDRX) to $30.00 (from $43.00) while maintaining a Buy rating following results.
The analyst commented, "We reiterate our Buy rating but lower our PT from $43 to $30 to reflect both lowered operating... More
March 1, 2022 4:58 AM EST
JPMorgan analyst Doug Anmuth lowered the price target on GoodRx Holdings Inc. (NASDAQ: GDRX) to $20.00 (from $33.00) while maintaining a Underweight rating.
The analyst comments "GoodRx is focused on building the top consumer-focused digital healthcare platform in the US. Its core offering tracks... More
February 28, 2022 5:31 PM EST
GoodRx Holdings, Inc. (NASDAQ: GDRX) shares were trading around 28% lower after-hours following the companys disappointing Q4 results. Quarterly EPS came in at $0.09, missing the consensus estimate of $0.10.
Revenue was $213.3 million, compared to the consensus estimate of $217.53 million. Prescription Transactions revenue increased 21% year-over-year... More
